Calcium Channel Expression and Applicability as Targeted Therapies in Melanoma

Macià, A.; Herreros, J.; Martí, R. M.; Cantí, C.

doi:https://doi.org/10.1155/2015/587135

BioMed Research International

On this page

Abstract Introduction Conclusions Abbreviations Disclosure Acknowledgments References Copyright Related Articles

Review Article Corrigendum

!

A Corrigendum for this article has been published. To view the article details, please click the ‘Corrigendum’ tab above.

Review Article | Open Access

Volume 2015 | Article ID 587135 | https://doi.org/10.1155/2015/587135

Calcium Channel Expression and Applicability as Targeted Therapies in Melanoma

A. Macià,¹J. Herreros,¹R. M. Martí,^1,2and C. Cantí¹

Academic Editor: Ajit S. Narang

Received17 Oct 2014

Revised15 Dec 2014

Accepted15 Dec 2014

Published01 Feb 2015

Abstract

The remodeling of Ca²⁺ signaling is a common finding in cancer pathophysiology serving the purpose of facilitating proliferation, migration, or survival of cancer cells subjected to stressful conditions. One particular facet of these adaptive changes is the alteration of Ca²⁺ fluxes through the plasma membrane, as described in several studies. In this review, we summarize the current knowledge about the expression of different Ca²⁺ channels in the plasma membrane of melanoma cells and its impact on oncogenic Ca²⁺ signaling. In the last few years, new molecular components of Ca²⁺ influx pathways have been identified in melanoma cells. In addition, new links between Ca²⁺ homeostasis and specific cell processes important in melanoma tumor progression have been unveiled. Thus, not only do Ca²⁺ channels appear to have a potential as prognostic markers, but their pharmacological blockade or gene silencing is hinted as interesting therapeutic approaches.

1. Introduction

Ionized calcium (Ca²⁺) is a ubiquitous second messenger that mediates several physiological functions, such as cell proliferation, survival, apoptosis, migration, and gene expression. The concentration of Ca²⁺ in the extracellular milieu is 1-2 mM whereas, at rest, intracellular Ca²⁺ is maintained at about 100 nM [1]. Specific Ca²⁺-transporters and Ca²⁺-binding proteins are used by cells to extrude Ca²⁺ through the plasma membrane, transport Ca²⁺ into the intracellular reservoirs, and buffer cytosolic Ca²⁺ [2, 3]. Conversely, there is a diversity of Ca²⁺ channels in the plasma membrane allowing Ca²⁺ entry into the cytosol. Ca²⁺ influx may cross-talk with Ca²⁺ channels present in the endoplasmic reticulum (ER), resulting in localized Ca²⁺ elevations that are decoded through a variety of Ca²⁺-dependent effectors [1, 4].

It has been long known that external Ca²⁺ is needed to induce cell proliferation and cell cycle progression in mammalian cells [5]. Some studies indicate a requirement of Ca²⁺ influx to induce a G1/S-phase during the cell cycle process [6, 7]. However, in cancer cells such requirement is modulated by the degree of cellular transformation, so that neoplastic or transformed cells continue proliferating in Ca²⁺-deficient media [8].

Several types of Ca²⁺ channels have been involved in cell cycle progression: transient receptor potential melastatin (TRPM), transient receptor potential vanilloid (TRPV), Transient Receptor Potential Canonical (TRPC), components of the store-operated calcium entry (SOCE) pathway such as Ca²⁺ influx channel (ORAI1) and endoplasmic Ca²⁺ depletion sensor (STIM1), and voltage-gated calcium channels (VGCCs) [5]. Through the use of in vitro models, a role for TRPC1, ORAI1, or STIM1 in Ca²⁺ signaling changes associated with the proliferation of endothelial cells has been uncovered [9, 10]. In addition, L- and T-type VGCCs have been shown to be upregulated during the S-phase in vascular smooth muscle cells [11, 12]. T-type channels appear to be specially suited for promoting cell cycle progression by virtue of their fast activation upon weak depolarization. This feature enables transient elevations of cytosolic Ca²⁺ in nonexcitable cells that signal to favor mitotic progression through direct binding of Ca²⁺ to intracellular effectors such as calmodulin (CaM) [4].

Ca²⁺ influx also plays an important role in tumor growth. Commonly, cancer cells present alterations of Ca²⁺ fluxes across the plasma membrane that reflect changes in the expression, subcellular localization, and/or function of different types of Ca²⁺ channels [13, 14]. Among them, the expression of different members of the TRP family has been shown to be altered in cancer cells. Particularly, TRPC3 is induced in breast and ovarian epithelial tumors, and TRPC6 is highly expressed in cancer of breast, liver, stomach, and esophagus and glioblastoma [14]. Similarly, the expression of TRPV1 and TRV4 is elevated in human hepatoblastoma and breast cancer cells, respectively [14, 15], and the expression level of TRPV6 correlates with tumor progression in prostate, thyroid, colon, ovarian, and breast cancers [16]. Moreover, TRPM8 is overexpressed in different carcinomas and has been proposed to be a “prooncogenic receptor” in prostate cancer cells [16, 17].

In addition, depletion of Ca²⁺ from the ER may drive tumor growth by inducing Ca²⁺ influx through the plasma membrane, as the expression of the SOCE canonical components STIM1 and ORAI1 is augmented in various cancer types, including breast cancer, glioblastoma, melanoma, and esophageal carcinoma (reviewed in [1, 14]).

VGCCs are also involved in cancer progression by generating oscillatory Ca²⁺ waves that favor cell cycle progression [18]. Heightened levels of L-type channel Ca_v1.2 mRNA have been reported in colorectal cancer [19]. Several studies have confirmed the increased expression of T-type Ca_v3.2 channels in breast, colon, prostate, ovarian, esophageal, and colon cancers and in glioblastoma, hepatoma, and melanoma [20]. However, hypermethylation of the T-type channel gene CACNA1G (that encodes the Ca_v3.1 isoform) occurs in different tumors including colon, pancreatic, and gastric cancer, suggesting that it acts as a tumor suppressor [21].

Cell physiology aspects other than proliferation are dependent on Ca²⁺ influx too. Through cell migration, Ca²⁺ signaling is involved in the directional sensing of the cells, in the redistribution and traction force of the cytoskeleton and in the repositioning of new focal adhesions [22, 23]. Cell migration is an early prerequisite for tumor metastasis with enormous impact on patient prognosis [23]. Members of the same Ca²⁺ channel families involved in tumor growth have been implicated in cancer cell migration and metastasis, such as TRP channels [24–26], STIM/ORAI-mediated SOCE [27–30], and T-type VGCCs [31, 32]. For example, TRPM7 has a promigratory effect on human nasopharyngeal carcinoma and its expression is related to metastasis formation [24], being a marker of poor prognosis in human breast cancer [25]. Nevertheless, TRPM1 expression in mice melanoma cells is reduced during metastasis [26]. Yang et al. provided evidence for the role of STIM1 and ORAI1 in the migration of the breast cancer cells using pharmacological blockers or siRNA [28]. The significance of STIM1 in focal adhesion and cell migration is extended to cervical cancer and hepatocellular carcinoma [29, 30]. Furthermore, it has been shown that T-type calcium channels regulate cell motility and migration in fibrosarcoma cells [31]. Conversely, Zhang et al. provided evidence for T-type channel blockers as dual inhibitors of proliferation and migration of human glioblastoma cells [32].

Finally, cell fate is also dependent on Ca²⁺ influx and its molecular machinery. Both the pharmacological blockade and the siRNA-mediated silencing of TRPM8 channels have been shown to induce the apoptotic death of prostate cancer cells [33], indicating a critical role for these channels in Ca²⁺ homeostasis maintenance. It has been suggested that TRPM8 could regulate either proliferation or apoptosis mechanism in prostate cells, depending on its intracellular localization [34]. Moreover, TRPV1 has been proposed as a useful target for killing malignant cells, since mitochondrial function was inhibited and apoptosis was induced in pancreatic cancer cells treated with a vanilloid analogue [8, 35]. VGCCs also play a relevant role in the survival of cancer cells. We have recently reported that T-type pharmacological blockers induce apoptosis in melanoma cells, in addition to reducing its proliferation [36]. Importantly, in the referred work the pharmacological results were backed up by siRNA-mediated silencing of Ca_v3.1 and Ca_v3.2 T-type channel isoforms. Likewise, Valerie et al. found that inhibition of T-type channels by a selective antagonist or siRNA-mediated gene knockdown not only reduced glioma cell viability but also induced apoptosis. These effects were reached via inhibition of the mTORC2/Akt pathway followed by a reduction in the phosphorylation of antiapoptotic Bad [37].

Hereon, this review will discuss the current knowledge about the role of different Ca²⁺ channels expressed in the plasma membrane of melanoma cells, as well as the Ca²⁺ signaling pathways involved during tumorigenesis and tumor progression.

2. Calcium Channels in Melanoma

Cutaneous melanoma is a malignant skin cancer that arises from transformed melanocytes de novo or from dysplastic, congenital, or common nevi [50]. Melanoma is the most dangerous form of skin cancer, and its incidence is steadily increasing worldwide. In spite of being the subject of intense laboratory investigations and numerous clinical trials, the prognosis of metastatic melanoma is still poor. New treatment strategies such as immunotherapy and specific gene therapy are currently under investigation.

2.1. Transient Receptor Potential Melastatin (TRPM) in Melanoma

TRP channels are known to regulate melanocyte physiology, particularly members of the TRPM subfamily [38]. Untransformed melanocytes express the full-length TRPM1 mRNA along with an alternative splicing variant (TRPM1-s) [51]. TRPM1 function appears to be critical to normal melanocyte pigmentation and melanogenesis, and thus this channel is a potential target for pigmentation disorders [52].

TRPM1 was first discovered in B16 mouse melanoma cell lines as a result of a differential display analysis [26]. This channel is strongly expressed in poorly metastatic B16 cells and expressed at reduced levels in the highly metastatic B16-F10 variant [26]. Moreover, in formalin-fixed tissue sections benign nevi were found to express high levels of TRPM1 that showed a low expression in primary melanomas whereas the full-length transcripts were not detected in melanoma metastases (but several short fragments of TRPM1) [26, 39]. As a matter of fact, several studies point to TRPM1 as a tumor suppressor in melanoma cells, as its loss of expression correlates with melanocytic tumor progression, metastatic potential, tumor thickness, and overall melanoma tumor aggressiveness (Figure 1; Table 1) [16, 26, 38–41]. In line with this, it has been suggested that the levels of TRPM1 mRNA can be used to predict the future development of metastatic melanoma [16, 38].

The regulation of TRPM1 gene expression has been extensively investigated. It has been proposed that TRPM1 expression in melanocytes and melanoma cells is regulated by a promoter region of the gene that contains four microphthalmia transcription factor (MITF) binding sites. Several groups demonstrated that MITF directly regulates the expression of TRPM1 in vitro and in vivo during melanoma progression [38, 42, 53, 54].

TRPM1 gene encodes both TRPM1 mRNA and miR-211 which is coded by the sixth intron of the gene. TRPM1 and miR-211 share the same promoter and are coregulated by MITF. Similar to TRPM1 protein, miR-211 is highly expressed in melanocytes and nevi and is reduced in melanoma cells [55, 56]. Consistently, overexpression of miR-211 exhibited significant growth inhibition and reduced migration and invasion in melanoma cells [38, 55–57].

Melanoma cells also express functional TRPM8 channels that produce a sustainable Ca²⁺ influx upon activation by menthol as agonist [43]. Strikingly, in this study the viability of melanoma cells was dose-dependently depressed in the presence of menthol, indicating that these channels underlie tumor progression via the Ca²⁺ handling pathway and suggesting TRPM8 Ca²⁺ channels as novel targets of drug development for malignant melanoma (Figure 1; Table 1).

Another member of the TRP family, TRPM2, is an ion channel capable of conferring susceptibility to cell death upon oxidative stress [58]. Quantitative RT-PCR experiments revealed that two antisense transcripts (TRPM2-AS and TRPM2-TE) from the TRPM2 gene were upregulated in melanoma cells and that their activation was linked to the hypermethylation of a shared CpG island. Moreover, knockdown of TRPM2-TE (proposed as a dominant-negative transcript) increased the vulnerability of melanoma cells to undergo apoptosis and necrosis, and overexpression of wild-type TRPM2 in melanoma cells leads to a faster proliferation (Figure 1; Table 1) [38, 44].

Finally, TRPM7 receptor has a protective and detoxifying function in normal and malignant melanocytes. In contrast to TRPM1, TRPM7 is highly expressed in metastatic melanoma (Figure 1; Table 1) [38, 45].

2.2. Store-Operated Ca²⁺ Entry (SOCE) in Melanoma

Ca²⁺ storage in the ER is an essential indicator of the proliferative, metabolic, and apoptotic status of cells. The retrograde signaling process from ER Ca²⁺ depletion to SOCE activation has a central role in many cellular and physiological functions. Indeed, SOCE is the main mechanism that implicates Ca²⁺ import from extracellular to intracellular space, especially in nonexcitable cells [59]. In the SOCE pathway, STIM proteins detect the depletion of Ca²⁺ at the ER and respond by translocating to the plasma membrane, where they activate ORAI Ca²⁺ channels and allow Ca²⁺ influx.

However, the role of SOCE in melanoma has not been investigated extensively. One study suggested a functional relevance for Ca²⁺-driven growth and survival of melanoma cells due to the control of SOCE by mitochondria [46]. The authors showed that coupling of mitochondria to SOCE allows the maintenance of strong Ca²⁺ fluxes and sustains a constitutive activation of PKB/Akt pathway, leading to an increased melanoma cell survival and resistance to apoptosis (Figure 1; Table 1). The same research group later demonstrated in vitro and in vivo that lipid rafts are critical for coupling SOCE to the constitutive activation of PKB/Akt in a Ca²⁺/calmodulin-, Src-, and PP2A-mediated pathway. These results underscore the potential of lipid raft disruptors as effective anticancer treatments [47].

More recently, Umemura et al. described that proliferation and migration are also regulated by SOCE in melanoma cells. They found that STIM1 and ORAI1 were expressed at high levels in human melanomas and melanoma cell lines. When SOCE activity was inhibited by pharmacological blockade or by siRNA-mediated gene knockdown, the proliferation rate was halted, cell migration was prevented, and metastasis progression was delayed (Figure 1; Table 1). Moreover, their results suggested that melanoma progression is promoted by SOCE through CaMKII/Raf-1/ERK signaling pathway, independently of BRAF mutations. Therefore, targeting SOCE could be a new strategy to treat a great number of melanoma patients, in monotherapy or in combination with BRAF inhibitors [48].

2.3. Voltage-Gated Ca²⁺ Channels (VGCCs) in Melanoma

In 2012, our research group reported that both normal melanocytes and transformed melanoma cells express functional VGCCs, including members of the Ca_v1 (L-type), Ca_v2 (N, P/Q or R-types), and Ca_v3 (T-type) families [49]. However, differences were noticed between the different cell lines regarding the expression of particular isoforms. Remarkably, untransformed melanocytes expressed only very low levels of T-type Ca_v3.1 channels, whereas transcripts for T-type Ca_v3.2 and Ca_v3.3 channels were undetectable. We also found a correlation between the proliferation rate and the expression of specific T-type channels isoforms, such that the melanoma cell lines displaying a high proliferation rate expressed higher levels of Ca_v3.2 channels (Figure 1; Table 1), whereas those ones growing slowly expressed preferentially the Ca_v3.1 isoform. Interestingly, the expression of these two T-type channel isoforms was counterbalanced. Furthermore, the results attained in gene knockdown experiments showed that whereas both Ca_v3.1 and Ca_v3.2 isoforms promote the progression of melanoma cells, the expression of Ca_v3.1 is associated with slow cycling and it is induced under hypoxic conditions [49]. In a follow-up study, we described that clinically used T-type channel pharmacological blockers induced G1/S cell cycle arrest and also triggered the apoptotic death of melanoma cells, which was partially dependent on mitochondrial caspase activation [36]. An in-depth analysis of the process revealed that apoptosis is preceded by ER stress and subsequent inhibition of the autophagic flux, which we found to be constitutively activated in melanoma cells (Figure 1; Table 1). These effects were mimicked by knockdown of Ca_v3.1 and Ca_v3.2 channels, thus allowing the identification of these T-type channels as novel targets to deregulate autophagy and induce cytotoxicity in melanoma cells [36].

3. Conclusions and Future Developments

Recent advances in the understanding of how Ca²⁺ influx is involved in melanoma tumorigenesis and progression may provide new targeted therapies for melanoma treatment. For this to materialize, it is essential to further deepen the study of the role of plasma membrane Ca²⁺ channels in melanoma cell proliferation and also in other less explored areas, such as migration or survival. In light of current knowledge, the selective activation of certain TRP channel isoforms and/or the development of humanized inhibitory antibodies to extracellular domains of TRP channels arise as putative therapeutic strategies [15, 16, 51]. Also, the blockade of Ca²⁺ influx through the use of pharmacological SOCE blockers and/or raft-targeting agents appears as an interesting approach to tackle melanoma progression [47, 48]. Finally, we highlight the potential of T-type Ca²⁺ channels as novel prognosis markers and/or therapeutic targets in melanoma. In this regard, our studies have uncovered a dual role of T-type Ca²⁺ channels in controlling melanoma cell proliferation and Ca²⁺ homeostasis, with an impact on adaptive cancer cell mechanisms like ER stress and macroautophagy that are often associated with chemotherapeutic or radiotherapeutic resistance [36, 49]. Thus, existing Ca²⁺ channel blockers may expand the pharmacological arsenal and become valuable partners for combined chemotherapies against melanoma.

Abbreviations

ER:	Endoplasmic reticulum
Ca²⁺:	Ionized calcium
TRPM:	Transient receptor potential melastatin
TRPV:	Transient receptor potential vanilloid
TRPC:	Transient receptor potential canonical
SOCE:	Store-operated calcium entry
VGCCs:	Voltage-gated calcium channels
BRAF:	v-raf murine sarcoma viral oncogene homolog B1.

Disclosure

R. M. Martí and C. Cantí are co-senior authors.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This research was supported by grants from ISCIII (PI1200260 to R. M. Martí and PI1301980 to J. Herreros) and grant from Fundació la Marató de TV3 (subproject 201331-31 to R. M. Martí).

References

T. A. Stewart, K. T. Yapa, and G. R. Monteith, “Altered calcium signaling in cancer cells,” Biochimica et Biophysica Acta (BBA)—Biomembranes, 2014.
View at: Publisher Site | Google Scholar
E. Carafoli, “The calcium-signalling saga: Tap water and protein crystals,” Nature Reviews Molecular Cell Biology, vol. 4, no. 4, pp. 326–332, 2003.
View at: Publisher Site | Google Scholar
A. M. Hofer and E. M. Brown, “Extracellular calcium sensing and signalling,” Nature Reviews Molecular Cell Biology, vol. 4, no. 7, pp. 530–538, 2003.
View at: Publisher Site | Google Scholar
C. R. Kahl and A. R. Means, “Regulation of cell cycle progression by calcium/calmodulin-dependent pathways,” Endocrine Reviews, vol. 24, no. 6, pp. 719–736, 2003.
View at: Publisher Site | Google Scholar
T. Capiod, “The need for calcium channels in cell proliferation,” Recent Patents on Anti-Cancer Drug Discovery, vol. 8, no. 1, pp. 4–17, 2013.
View at: Publisher Site | Google Scholar
A. L. Boynton, J. F. Whitfield, R. J. Isaacs, and R. G. Tremblay, “Different extracellular calcium requirements for proliferation of nonneoplastic, preneoplastic, and neoplastic mouse cells,” Cancer Research, vol. 37, no. 8, pp. 2657–2661, 1977.
View at: Google Scholar
N. Takuwa, W. Zhou, and Y. Takuwa, “Calcium, calmodulin and cell cycle progression,” Cellular Signalling, vol. 7, no. 2, pp. 93–104, 1995.
View at: Publisher Site | Google Scholar
G. Shapovalov, V. Lehen'kyi, R. Skryma, and N. Prevarskaya, “TRP channels in cell survival and cell death in normal and transformed cells,” Cell Calcium, vol. 50, no. 3, pp. 295–302, 2011.
View at: Publisher Site | Google Scholar
B. Kumar, K. Dreja, S. S. Shah et al., “Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia,” Circulation Research, vol. 98, no. 4, pp. 557–563, 2006.
View at: Publisher Site | Google Scholar
W. Zhang, K. E. Halligan, X. Zhang et al., “Orai1-mediated $I_{C R A C}$ is essential for neointima formation after vascular injury,” Circulation Research, vol. 109, no. 5, pp. 534–542, 2011.
View at: Publisher Site | Google Scholar
L. L. Cribbs, “T-type Ca²⁺ channels in vascular smooth muscle: Multiple functions,” Cell Calcium, vol. 40, no. 2, pp. 221–230, 2006.
View at: Publisher Site | Google Scholar
T. Kuga, S. Kobayashi, Y. Hirakawa, H. Kanaide, and A. Takeshita, “Cell cycle—dependent expression of L- and T-type Ca²⁺ currents in rat aortic smooth muscle cells in primary culture,” Circulation Research, vol. 79, no. 1, pp. 14–19, 1996.
View at: Publisher Site | Google Scholar
G. R. Monteith, D. McAndrew, H. M. Faddy, and S. J. Roberts-Thomson, “Calcium and cancer: targeting Ca²⁺ transport,” Nature Reviews Cancer, vol. 7, no. 7, pp. 519–530, 2007.
View at: Publisher Site | Google Scholar
G. R. Monteith, F. M. Davis, and S. J. Roberts-Thomson, “Calcium channels and pumps in cancer: changes and consequences,” The Journal of Biological Chemistry, vol. 287, no. 38, pp. 31666–31673, 2012.
View at: Publisher Site | Google Scholar
M. Bödding, “TRP proteins and cancer,” Cellular Signalling, vol. 19, no. 3, pp. 617–624, 2007.
View at: Publisher Site | Google Scholar
N. Prevarskaya, L. Zhang, and G. Barritt, “TRP channels in cancer,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1772, no. 8, pp. 937–946, 2007.
View at: Publisher Site | Google Scholar
L. Tsavaler, M. H. Shapero, S. Morkowski, and R. Laus, “Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins,” Cancer Research, vol. 61, no. 9, pp. 3760–3769, 2001.
View at: Google Scholar
T. Capiod, “Cell proliferation, calcium influx and calcium channels,” Biochimie, vol. 93, no. 12, pp. 2075–2079, 2011.
View at: Publisher Site | Google Scholar
X.-T. Wang, Y. Nagaba, H. S. Cross, F. Wrba, L. Zhang, and S. E. Guggino, “The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon,” The American Journal of Pathology, vol. 157, no. 5, pp. 1549–1562, 2000.
View at: Publisher Site | Google Scholar
B. Dziegielewska, L. S. Gray, and J. Dziegielewski, “T-type calcium channels blockers as new tools in cancer therapies,” Pflügers Archiv, vol. 466, no. 4, pp. 801–810, 2014.
View at: Publisher Site | Google Scholar
P. Lory, I. Bidaud, and J. Chemin, “T-type calcium channels in differentiation and proliferation,” Cell Calcium, vol. 40, no. 2, pp. 135–146, 2006.
View at: Publisher Site | Google Scholar
A. J. Ridley, M. A. Schwartz, K. Burridge et al., “Cell migration: integrating signals from front to back,” Science, vol. 302, no. 5651, pp. 1704–1709, 2003.
View at: Publisher Site | Google Scholar
N. Prevarskaya, R. Skryma, and Y. Shuba, “Calcium in tumour metastasis: new roles for known actors,” Nature Reviews Cancer, vol. 11, no. 8, pp. 609–618, 2011.
View at: Publisher Site | Google Scholar
J.-P. Chen, Y. Luan, C.-X. You, X.-H. Chen, R.-C. Luo, and R. Li, “TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca²⁺ influx,” Cell Calcium, vol. 47, no. 5, pp. 425–432, 2010.
View at: Publisher Site | Google Scholar
J. Middelbeek, A. J. Kuipers, L. Henneman et al., “TRPM7 is required for breast tumor cell metastasis,” Cancer Research, vol. 72, no. 16, pp. 4250–4261, 2012.
View at: Publisher Site | Google Scholar
L. M. Duncan, J. Deeds, J. Hunter et al., “Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis,” Cancer Research, vol. 58, no. 7, pp. 1515–1520, 1998.
View at: Google Scholar
Y.-F. Chen, Y.-T. Chen, W.-T. Chiu, and M.-R. Shen, “Remodeling of calcium signaling in tumor progression,” Journal of Biomedical Science, vol. 20, article 23, 2013.
View at: Publisher Site | Google Scholar
S. Yang, J. J. Zhang, and X.-Y. Huang, “Orai1 and STIM1 are critical for breast tumor cell migration and metastasis,” Cancer Cell, vol. 15, no. 2, pp. 124–134, 2009.
View at: Publisher Site | Google Scholar
Y.-F. Chen, W.-T. Chiu, Y.-T. Chen et al., “Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis,” Proceedings of the National Academy of Sciences, vol. 108, no. 37, pp. 15225–15230, 2011.
View at: Publisher Site | Google Scholar
N. Yang, Y. Tang, F. Wang et al., “Blockade of store-operated Ca²⁺ entry inhibits hepatocarcinoma cell migration and invasion by regulating focal adhesion turnover,” Cancer Letters, vol. 330, no. 2, pp. 163–169, 2013.
View at: Publisher Site | Google Scholar
J.-B. Huang, A. L. Kindzelskii, A. J. Clark, and H. R. Petty, “Identification of channels promoting calcium spikes and waves in HT1080 tumor cells: their apparent roles in cell motility and invasion,” Cancer Research, vol. 64, no. 7, pp. 2482–2489, 2004.
View at: Publisher Site | Google Scholar
Y. Zhang, J. Zhang, D. Jiang et al., “Inhibition of T-type Ca²⁺ channels by endostatin attenuates human glioblastoma cell proliferation and migration,” British Journal of Pharmacology, vol. 166, no. 4, pp. 1247–1260, 2012.
View at: Publisher Site | Google Scholar
L. Zhang and G. J. Barritt, “Evidence that TRPM8 is an androgen-dependent Ca²⁺ channel required for the survival of prostate cancer cells,” Cancer Research, vol. 64, no. 22, pp. 8365–8373, 2004.
View at: Publisher Site | Google Scholar
G. Bidaux, M. Flourakis, S. Thebault et al., “Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function,” Journal of Clinical Investigation, vol. 117, no. 6, pp. 1647–1657, 2007.
View at: Publisher Site | Google Scholar
M. Hartel, F. F. Di Mola, F. Selvaggi et al., “Vanilloids in pancreatic cancer: potential for chemotherapy and pain management,” Gut, vol. 55, no. 4, pp. 519–528, 2006.
View at: Publisher Site | Google Scholar
A. Das, C. Pushparaj, J. Herreros et al., “T-type calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells,” Pigment Cell and Melanoma Research, vol. 26, no. 6, pp. 874–885, 2013.
View at: Publisher Site | Google Scholar
N. C. K. Valerie, B. Dziegielewska, A. S. Hosing et al., “Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells,” Biochemical Pharmacology, vol. 85, no. 7, pp. 888–897, 2013.
View at: Publisher Site | Google Scholar
H. Guo, J. A. Carlson, and A. Slominski, “Role of TRPM in melanocytes and melanoma,” Experimental Dermatology, vol. 21, no. 9, pp. 650–654, 2012.
View at: Publisher Site | Google Scholar
D. Fang and V. Setaluri, “Expression and up-regulation of alternatively spliced transcripts of melastatin, a melanoma metastasis-related gene, in human melanoma cells,” Biochemical and Biophysical Research Communications, vol. 279, no. 1, pp. 53–61, 2000.
View at: Publisher Site | Google Scholar
J. Deeds, F. Cronin, and L. M. Duncan, “Patterns of melastatin mRNA expression in melanocytic tumors,” Human Pathology, vol. 31, no. 11, pp. 1346–1356, 2000.
View at: Publisher Site | Google Scholar
L. M. Duncan, J. Deeds, F. E. Cronin et al., “Melastatin expression and prognosis in cutaneous malignant melanoma,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 568–576, 2001.
View at: Google Scholar
A. J. Miller, J. Du, S. Rowan, C. L. Hershey, H. R. Widlund, and D. E. Fisher, “Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma,” Cancer Research, vol. 64, no. 2, pp. 509–516, 2004.
View at: Publisher Site | Google Scholar
H. Yamamura, S. Ugawa, T. Ueda, A. Morita, and S. Shimada, “TRPM8 activation suppresses cellular viability in human melanoma,” The American Journal of Physiology—Cell Physiology, vol. 295, no. 2, pp. C296–C301, 2008.
View at: Publisher Site | Google Scholar
U. Orfanelli, A.-K. Wenke, C. Doglioni, V. Russo, A. K. Bosserhoff, and G. Lavorgna, “Identification of novel sense and antisense transcription at the TRPM2 locus in cancer,” Cell Research, vol. 18, no. 11, pp. 1128–1140, 2008.
View at: Publisher Site | Google Scholar
M. S. McNeill, J. Paulsen, G. Bonde, E. Burnight, M.-Y. Hsu, and R. A. Cornell, “Cell death of melanophores in zebrafish trpm7 mutant embryos depends on melanin synthesis,” Journal of Investigative Dermatology, vol. 127, no. 8, pp. 2020–2030, 2007.
View at: Publisher Site | Google Scholar
B. Feldman, S. Fedida-Metula, J. Nita, I. Sekler, and D. Fishman, “Coupling of mitochondria to store-operated Ca²⁺-signaling sustains constitutive activation of protein kinase B/Akt and augments survival of malignant melanoma cells,” Cell Calcium, vol. 47, no. 6, pp. 525–537, 2010.
View at: Publisher Site | Google Scholar
S. Fedida-Metula, B. Feldman, V. Koshelev, U. Levin-Gromiko, E. Voronov, and D. Fishman, “Lipid rafts couple store-operated Ca²⁺ entry to constitutive activation of PKB/Akt in a Ca²⁺/calmodulin-, Src- and PP2A-mediated pathway and promote melanoma tumor growth,” Carcinogenesis, vol. 33, no. 4, pp. 740–750, 2012.
View at: Publisher Site | Google Scholar
M. Umemura, E. Baljinnyam, S. Feske et al., “Store-operated Ca²⁺ entry (SOCE) regulates melanoma proliferation and cell migration,” PLoS ONE, vol. 9, no. 2, Article ID e89292, 2014.
View at: Publisher Site | Google Scholar
A. Das, C. Pushparaj, N. Bahí et al., “Functional expression of voltage-gated calcium channels in human melanoma,” Pigment Cell and Melanoma Research, vol. 25, no. 2, pp. 200–212, 2012.
View at: Publisher Site | Google Scholar
S. C. Weatherhead, M. Haniffa, and C. M. Lawrence, “Melanomas arising from naevi and de novo melanomas—does origin matter?” British Journal of Dermatology, vol. 156, no. 1, pp. 72–76, 2007.
View at: Publisher Site | Google Scholar
D. Gkika and N. Prevarskaya, “Molecular mechanisms of TRP regulation in tumor growth and metastasis,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1793, no. 6, pp. 953–958, 2009.
View at: Publisher Site | Google Scholar
E. Oancea, J. Vriens, S. Brauchi, J. Jun, I. Splawski, and D. E. Clapham, “TRPM1 forms ion channels associated with melanin content in melanocytes,” Science Signaling, vol. 2, no. 70, article ra21, 2009.
View at: Publisher Site | Google Scholar
S. Zhiqi, M. H. Soltani, K. M. R. Bhat et al., “Human melastatin 1 (TRPM1) is regulated by MITF and produces multiple polypeptide isoforms in melanocytes and melanoma,” Melanoma Research, vol. 14, no. 6, pp. 509–516, 2004.
View at: Publisher Site | Google Scholar
S. Lu, A. Slominski, S.-E. Yang, C. Sheehan, J. Ross, and J. A. Carlson, “The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesis-related proteins in normal and pathological skin, hair follicles and melanocytic nevi,” Journal of Cutaneous Pathology, vol. 37, no. 1, pp. 26–40, 2010.
View at: Publisher Site | Google Scholar
C. Levy, M. Khaled, D. Iliopoulos et al., “Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma,” Molecular Cell, vol. 40, no. 5, pp. 841–849, 2010.
View at: Publisher Site | Google Scholar
G. M. Boyle, S. L. Woods, V. F. Bonazzi et al., “Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor,” Pigment Cell and Melanoma Research, vol. 24, no. 3, pp. 525–537, 2011.
View at: Publisher Site | Google Scholar
J. Mazar, K. de Young, D. Khaitan et al., “The regulation of miRNA-211 expression and its role in melanoma cell invasiveness,” PLoS ONE, vol. 5, no. 11, Article ID e13779, 2010.
View at: Publisher Site | Google Scholar
S.-J. Chen, W. Zhang, Q. Tong et al., “Role of TRPM2 in cell proliferation and susceptibility to oxidative stress,” American Journal of Physiology—Cell Physiology, vol. 304, no. 6, pp. C548–C560, 2013.
View at: Publisher Site | Google Scholar
J. W. Putney Jr., “Capacitative calcium entry: sensing the calcium stores,” Journal of Cell Biology, vol. 169, no. 3, pp. 381–382, 2005.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2015 A. Macià et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1764

Downloads

1087

Citations

BioMed Research International

Calcium Channel Expression and Applicability as Targeted Therapies in Melanoma

Abstract

1. Introduction

2. Calcium Channels in Melanoma

2.1. Transient Receptor Potential Melastatin (TRPM) in Melanoma

2.2. Store-Operated Ca2+ Entry (SOCE) in Melanoma

2.3. Voltage-Gated Ca2+ Channels (VGCCs) in Melanoma

3. Conclusions and Future Developments

Abbreviations

Disclosure

Conflict of Interests

Acknowledgments

References

Copyright

2.2. Store-Operated Ca²⁺ Entry (SOCE) in Melanoma

2.3. Voltage-Gated Ca²⁺ Channels (VGCCs) in Melanoma